
a
HR (Atezo vs. Doce), SDI-High patients
HR (Atezo vs. Doce), SDI-Low patients
Interaction p-val
OS Hazard Ratio
Interaction p-value
SDI cutoff point
PFS Hazard Ratio
b
SDI−H & Docetaxel
SDI−H & Atezolizumab
SDI−L & Docetaxel
SDI−L & Atezolizumab
Overall Survival (%)
SDI cut-off = 1.42
Interaction p-val = 0.388
Time in Months
Number at risk
190 107 44 21 3
202 122 82 55 6
201 135 76 45 9
192 154 112 83 15
Progression−free Survival (%)
SDI cut-off = 1.42
Interaction p-val = 0.954
190 36 17 4 0
202 54 33 22 3
201 57 17 7 1
192 71 39 21 1
c
Spearman's rank correlation rho
rho = 0.751, p < 0.001
ShannonIndex
MSAF
d
Spearman's rank correlation rho
rho = 0.674, p < 0.001
Mutation counts